Business Context and Reporting Period
This Form 8-K is a Current Report filed by Alpha Healthcare Acquisition Corp. (AHAC) on May 21, 2021. The filing primarily serves to disclose a press release issued by Humacyte, Inc., a clinical-stage biotechnology company. AHAC and Humacyte previously announced a definitive Business Combination Agreement on February 17, 2021, under which Humacyte will merge with a subsidiary of AHAC.
Key Financial Metrics
This filing is a disclosure of a corporate event and scientific update; it does not contain financial statements, revenue figures, profit data, cash flow metrics, debt levels, or liquidity ratios for either AHAC or Humacyte. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Events
- Scientific Update: Humacyte announced new findings from cross-species alveolar studies in laboratory and pre-clinical models. These findings support the potential to engineer functional lung alveoli.
- Merger Status: The filing reiterates the pending Business Combination between AHAC and Humacyte. Hunter Merger Sub, Inc. is set to merge with and into Humacyte, with Humacyte surviving as a wholly-owned subsidiary of AHAC.
- Regulatory Disclosure: The press release regarding the scientific findings is attached as Exhibit 99.1 and incorporated by reference under Item 7.01 (Regulation FD Disclosure).
Guidance, Outlook, and Risks
Outlook and Management Commentary: The filing includes extensive forward-looking statements regarding the proposed Business Combination, including its timing, structure, proceeds, and the anticipated benefits. It also references Humacyte's product development activities and clinical trial timelines. Management cautions that these statements are based on current beliefs and assumptions.
Risks and Contingencies: The filing highlights significant risks that could cause actual results to differ materially from expectations, including:
- Failure to obtain approval from AHAC stockholders or satisfy other closing conditions.
- Events leading to the termination of the Business Combination Agreement.
- Legal proceedings instituted against AHAC or Humacyte.
- The impact of the COVID-19 pandemic on Humacyte's business and the merger completion.
- Ability to maintain Nasdaq listing for AHAC's Class A Common Stock post-combination.
- Economic, business, and competitive factors.
Next Steps: A full description of the merger terms will be provided in a registration statement on Form S-4, which will include a proxy statement/prospectus for AHAC stockholders to vote on the Business Combination.
Investor Verification Checklist
- Verify the details of the Business Combination Agreement filed on February 17, 2021 (Exhibit 2.1 to AHAC's prior 8-K).
- Review the attached Press Release (Exhibit 99.1) for specific data on the cross-species alveolar studies.
- Monitor the upcoming Form S-4 Registration Statement for the definitive proxy statement/prospectus and merger terms.
- Assess the Risk Factors detailed in the S-4 and AHAC's final IPO prospectus regarding the merger's completion and Humacyte's clinical pipeline.
- Confirm the stockholder vote requirements and record date for the AHAC proxy meeting once established.